Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 1:9:3393-404.
doi: 10.2147/DDDT.S85633. eCollection 2015.

Scientometrics of drug discovery efforts: pain-related molecular targets

Affiliations

Scientometrics of drug discovery efforts: pain-related molecular targets

Igor Kissin. Drug Des Devel Ther. .

Abstract

The aim of this study was to make a scientometric assessment of drug discovery efforts centered on pain-related molecular targets. The following scientometric indices were used: the popularity index, representing the share of articles (or patents) on a specific topic among all articles (or patents) on pain over the same 5-year period; the index of change, representing the change in the number of articles (or patents) on a topic from one 5-year period to the next; the index of expectations, representing the ratio of the number of all types of articles on a topic in the top 20 journals relative to the number of articles in all (>5,000) biomedical journals covered by PubMed over a 5-year period; the total number of articles representing Phase I-III trials of investigational drugs over a 5-year period; and the trial balance index, a ratio of Phase I-II publications to Phase III publications. Articles (PubMed database) and patents (US Patent and Trademark Office database) on 17 topics related to pain mechanisms were assessed during six 5-year periods from 1984 to 2013. During the most recent 5-year period (2009-2013), seven of 17 topics have demonstrated high research activity (purinergic receptors, serotonin, transient receptor potential channels, cytokines, gamma aminobutyric acid, glutamate, and protein kinases). However, even with these seven topics, the index of expectations decreased or did not change compared with the 2004-2008 period. In addition, publications representing Phase I-III trials of investigational drugs (2009-2013) did not indicate great enthusiasm on the part of the pharmaceutical industry regarding drugs specifically designed for treatment of pain. A promising development related to the new tool of molecular targeting, ie, monoclonal antibodies, for pain treatment has not yet resulted in real success. This approach has not yet demonstrated clinical effectiveness (at least with nerve growth factor) much beyond conventional analgesics, when its potential cost is more than an order of magnitude higher than that of conventional treatments. This scientometric assessment demonstrated a lack of real breakthrough developments.

Keywords: analgesics; bibliometrics; biomedical journals; drug design; patents; pharmaceutical industry.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time courses of popularity indices related to patents and articles for TRP channels (A) and serotonin (B). Notes: The article-related popularity index is the percentage of articles on a topic among all articles on pain published over the same 5-year period. Similarly, the patent-related popularity index is the percentage of patents on a topic among all US patents pertinent to pain. The figure indicates that changes in the patent-related popularity index on these two topics occur faster than for the article-related popularity index. Abbreviation: TRP, transient receptor potential.

Similar articles

Cited by

References

    1. Kissin I. Can a bibliometric indicator predict the success of a drug? Scientometrics. 2011;86:785–795.
    1. Kissin I, Bradley EL., Jr Top Journals Selectivity Index: is it acceptable for drugs beyond the field of analgesia? Scientometrics. 2011;88:589–597.
    1. Kissin I, Bradley EL., Jr Top Journal Selectivity Index and ‘me-too’ drugs. Scientometrics. 2012;91:131–142.
    1. Kissin I. An early indicator of drug success: Top Journal Selectivity Index. Drug Des Devel Ther. 2013;7:93–98. - PMC - PubMed
    1. Correll DJ, Vlassakov KV, Kissin I. No evidence of real progress in treatment of acute pain, 1993–2012: scientometric analysis. J Pain Res. 2014;7:199–210. - PMC - PubMed

MeSH terms